A
Arcus Biosciences, Inc. (RCUS)
NYQ – Real vaqt narxi. Valyuta: USD
31.00
+0.75 (2.48%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
31.36
+0.36 (1.16%)
Bozordan keyin: Jun 26, 2026, 5:57 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NYQ – Real vaqt narxi. Valyuta: USD
31.00
+0.75 (2.48%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
31.36
+0.36 (1.16%)
Bozordan keyin: Jun 26, 2026, 5:57 PM EDT
Arcus Biosciences, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda saratonni davolash usullarini ishlab chiqadi va tijoratlashtiradi. Kompaniyaning ishlab chiqish mahsulotlari portfeliga buyrak saratonini davolash uchun HIF-2α ingibitori bo'lgan Casdatifan; o'pka va oshqozon-ichak saratonlari uchun 2- va 3-bosqich klinik sinovlarida bo'lgan anti-TIGIT antikori Domvanalimab; va anti-PD-1 antikori Zimberelimab kiradi. Shuningdek, u o'pka va oshqozon osti bezi saratonini davolash uchun 3- va 1/1b-bosqich klinik sinovlarida bo'lgan ATP-adenozin yo'lidagi CD73 fermentini nishonga oluvchi kichik molekulali ingibitor Quemliclustatni ishlab chiqadi. Qo'shimcha ravishda, kompaniya oshqozon-ichak saratonini davolash uchun 1/1b-bosqich klinik tadqiqotida bo'lgan CD39 antikori AB598 va o'pka saratonini davolash uchun 1b-bosqich klinik sinovida bo'lgan AXL ingibitori AB801ni ishlab chiqadi. U AstraZeneca bilan 3-bosqich PACIFIC-8 sinovida domvanalimab va durvalumabni 3-bosqichli NSCLCda baholash uchun va IO-naive ccRCC bemorlarida kasdatifan va volrustomigni baholash uchun 1/1b-bosqichli tadqiqotda klinik hamkorlikni amalga oshiradi; yallig'lanish kasalliklarini davolash uchun birikmalarni kashf qilish va ishlab chiqishni qo'llab-quvvatlash uchun BVF Partners L.P.; va buyrak saratonida o'smalarni nazorat qilishni ta'minlovchi noyob davolash rejimini ishlab chiqish uchun Bristol-Myers Squibb Company bilan hamkorlik qiladi. Arcus Biosciences, Inc. 2015 yilda tashkil etilgan va Xeyvord, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Jonathan Yingling Ph.D. | Chief Scientific Officer |
| Dr. Juan Carlos Jaen Ph.D. | Co- Founder & President |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Richard A. Markus M.D., Ph.D. | Chief Medical Officer |
| Dr. Terry J. Rosen Ph.D. | Co-Founder, Chairman & CEO |
| Mr. Alexander Azoy CPA | Chief Accounting Officer |
| Mr. Robert C. Goeltz II | Principal Financial Officer & CFO |
| Ms. Carolyn C. Tang J.D. | General Counsel & Corporate Secretary |
| Ms. Jennifer A. Jarrett M.B.A. | Advisor |
| Pia Eaves | Vice President of Investor Relations & Strategy |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-12 | 8-K | rcus-20260611.htm |
| 2026-05-05 | 8-K | rcus-20260505.htm |
| 2026-05-05 | 10-Q | rcus-20260331.htm |
| 2026-04-21 | DEFA14A | arcusfy2026proxynotice.htm |
| 2026-04-21 | DEF 14A | rcus-20260421.htm |
| 2026-04-21 | ARS | fy2025annualreporttoshareh.pdf |
| 2026-04-20 | 8-K | rcus-20260420.htm |
| 2026-03-23 | 8-K | rcus-20260317.htm |
| 2026-02-25 | S-8 | rcus_fyx2026xs-8.htm |
| 2026-02-25 | S-3ASR | d274489ds3asr.htm |